Foxx Development (NASDAQ:FOXX) CTO Sells $11,949.45 in Stock

Foxx Development Holdings Inc. (NASDAQ:FOXX) CTO James Liao sold 1,943 shares of the stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $6.15, for a total value of $11,949.45. Following the completion of the sale, the chief technology officer owned 19,431 shares in the company, valued at approximately $119,500.65. The trade was a 9.09% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Foxx Development Stock Performance

Shares of NASDAQ FOXX opened at $5.06 on Monday. The stock has a market cap of $35.62 million, a P/E ratio of -0.74 and a beta of -0.30. Foxx Development Holdings Inc. has a 12-month low of $1.71 and a 12-month high of $8.88. The business’s fifty day simple moving average is $4.70 and its 200-day simple moving average is $4.54.

Foxx Development (NASDAQ:FOXX) last announced its quarterly earnings data on Wednesday, May 20th. The company reported ($5.19) earnings per share (EPS) for the quarter. The firm had revenue of $8.67 million during the quarter.

Institutional Trading of Foxx Development

An institutional investor recently raised its position in Foxx Development stock. JPMorgan Chase & Co. raised its holdings in Foxx Development Holdings Inc. (NASDAQ:FOXX) by 170.9% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,947 shares of the company’s stock after buying an additional 3,121 shares during the period. JPMorgan Chase & Co. owned about 0.07% of Foxx Development worth $27,000 as of its most recent SEC filing. 60.44% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings cut Foxx Development from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 2nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Foxx Development Company Profile

Foxx Development, Inc (NASDAQ: FOXX) operates as a contract manufacturer specializing in the design, assembly and distribution of medical devices and components. The company’s core business centers on phlebotomy and blood collection products, serving clinical laboratories, hospitals and diagnostic testing facilities. Its product portfolio includes evacuated blood collection tubes, safety-engineered winged blood collection sets, syringes and ancillary devices used in specimen collection and handling.

Founded in North Carolina, Foxx Development maintains a manufacturing and distribution campus in Apex, where it integrates engineering, quality control and regulatory compliance under one roof.